Karen M. Cichowski
Affiliations: | Harvard University, Cambridge, MA, United States |
Area:
Cell Biology, Molecular BiologyGoogle:
"Karen Cichowski"Children
Sign in to add trainee| Cory M. Johannessen | grad student | 2008 | Harvard |
| Lauren T. McGillicuddy | grad student | 2008 | Harvard |
| Pablo E. Hollstein | grad student | 2009 | Harvard |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Loi P, Schade AE, Rodriguez CL, et al. (2024) Epigenetic and oncogenic inhibitors cooperatively drive differentiation and kill KRAS-mutant colorectal cancers. Cancer Discovery |
| Perurena N, Cichowski K. (2024) Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue. Cancer Cell. 42: 943-945 |
| Perurena N, Situ L, Cichowski K. (2024) Combinatorial strategies to target RAS-driven cancers. Nature Reviews. Cancer. 24: 316-337 |
| Min J, Zaslavsky A, Fedele G, et al. (2024) Author Correction: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Nature Medicine |
| Nardi F, Perurena N, Schade AE, et al. (2023) Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer. The Journal of Clinical Investigation |
| Perurena N, Lock R, Davis RA, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Reports. Medicine. 101007 |
| Miller AL, Perurena N, Gardner A, et al. (2023) DAB2IP is a bifunctional tumor suppressor that regulates wildtype RAS and inflammatory cascades in KRAS mutant colon cancer. Cancer Research |
| Zhang Y, Guillermier C, De Raedt T, et al. (2020) Imaging Mass Spectrometry Reveals Tumor Metabolic Heterogeneity. Iscience. 23: 101355 |
| Guerra SL, Maertens O, Kuzmickas R, et al. (2020) A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell |
| Tian T, Lofftus S, Pan Y, et al. (2020) IL1α antagonizes IL1β and promotes adaptive immune rejection of malignant tumors. Cancer Immunology Research |